Ubenimex is under clinical development by Nippon Kayaku and currently in Phase II for Squamous Non-Small Cell Lung Carcinoma. According to GlobalData, Phase II drugs for Squamous Non-Small Cell Lung Carcinoma have a 17% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ubenimex’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ubenimex (Bestatin) is an anti-cancer agent and immunomodulator. Bestatin is under development for the treatment of squamous non-small cell lung carcinoma. It is formulated as capsules for oral route of administration.
It was under development for lymphedema and pulmonary arterial hypertension.
Nippon Kayaku overview
Nippon Kayaku is a chemical company, which undertakes the development, manufacturing and sale of functional chemicals, pharmaceuticals, safety systems and agrochemicals. The company’s product portfolio includes epoxy resins, UV-curing type resins, optical functional films, colors for inkjet printers, catalysts, pharmaceuticals, active pharmaceutical ingredients, intermediates, diagnostic drugs, safety systems such as airbag inflators, micro gas generators for seatbelt pretensioners, squibs, agrochemicals, dyes and others. The company also offers real estate leasing and contract manufacturing to pharmaceutical companies. It has subsidiaries in companies in North America, Europe and Asia. Nippon Kayaku is headquartered in Chiyoda-ku, Tokyo, Japan.
For a complete picture of Ubenimex’s drug-specific PTSR and LoA scores, buy the report here.